SCHEMBL4033705

SCHEMBL4033705

Nc1nccc(-c2ccc3noc(-c4ccc(N5CCOCC5)cc4)c3c2)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.67
CDK1 P06493 1/20 0.53
CDK2 P24941 1/20 0.53
IP6K1 Q92551 1/20 0.46
IP6K3 Q96PC2 1/20 0.46
IP6K2 Q9UHH9 1/20 0.46
JAK2 O60674 8/20 0.45
PIK3CD O00329 1/20 0.44
PIK3R1 P27986 1/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
MAPK10 P53779 1/20 0.43
MYLK4 Q86YV6 2/20 0.43
STK17A Q9UEE5 2/20 0.43
MAPKAPK2 P49137 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4027259 0.92 PIM1 (0.67) PIM1CDK1CDK2IP6K1IP6K3
SCHEMBL13811881 0.90 PIM1 (0.65) PIM1CDK1CDK2IP6K1IP6K3
SCHEMBL13908922 0.88 PIM1 (0.59) PIM1CDK1CDK2PIK3CDPIK3R1
SCHEMBL13811985 0.84 PIM1 (0.60) PIM1CDK1CDK2IP6K1IP6K3
SCHEMBL13812005 0.83 PIM1 (0.58) PIM1CDK1CDK2IP6K1IP6K3
SCHEMBL4025115 0.82 PIM1 (0.60) PIM1CDK1CDK2IP6K1IP6K3
SCHEMBL4466816 0.81 CDK1 (0.66) CDK1CDK2JAK2PIK3CDPIK3R1
SCHEMBL14499938 0.81 PIM1 (0.59) PIM1CDK1CDK2IP6K1IP6K3
SCHEMBL4031585 0.81 PIM1 (1.00) PIM1CDK2NPC1RAB9AKDM4E
SCHEMBL4027680 0.81 PIM1 (0.78) PIM1CDK1CDK2IP6K1IP6K3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399440-B1 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2009-06-03 EP disclosed
US-20050228005-A1 Protein kinase inhibitors and uses thereof MOON YOUNG C 2005-10-13 US disclosed
US-6825190-B2 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES VERTEX PHARMACEUTICALS INCORPORATED 2004-11-30 US disclosed
US-20040009996-A1 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009996-A1 Protein kinase inhibitors and uses thereof GSK3A, GSK3B, JAK3 PIM1 425/4885CDK1 19/4885CDK2 49/4885
US-20050228005-A1 Protein kinase inhibitors and uses thereof GSK3A, JAK3, GSK3B PIM1 536/4885CDK1 14/4885CDK2 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.